New studies unravel mysteries of how PARP enzymes work

February 16, 2017, UT Southwestern Medical Center

A component of an enzyme family linked to DNA repair, stress responses, and cancer also plays a role in enhancing or inhibiting major cellular activities under physiological conditions, new research shows.

The UT Southwestern Medical Center research focused on PARP-1, a member of the PARP enzyme family. Short for poly (ADP-ribose) polymerase, PARP became the focus of attention in 2014 with approval of the first PARP inhibitor drug to treat advanced ovarian cancer associated with mutant BRCA DNA repair genes. The drug, Lynparza or olaparib, blocks nuclear PARP enzymes, inhibiting DNA repair even further and causing genome instability that kills the cancer cells.

In two related studies published in Molecular Cell, UT Southwestern scientists describe how PARP-1 can act at a molecular level under physiological conditions to reduce the formation of fat cell precursors and to help maintain the unique ability of embryonic to self-renew and become any of a variety of different cell types. One of the studies is published online today; the earlier study posted Jan. 19.

PARP-1's role in these cellular processes occurs during gene transcription, when DNA is copied into messenger RNA molecules, which can then be used as a template to produce new proteins.

Researchers already knew about PARP's role in DNA damage-related diseases like cancer, said Dr. W. Lee Kraus, senior author of both UTSW studies and Professor of Obstetrics and Gynecology, and Pharmacology at UT Southwestern. Dr. Kraus also directs the Cecil H. and Ida Green Center for Reproductive Biology Sciences and holds the Cecil H. and Ida Green Distinguished Chair in Reproductive Biology Sciences.

These findings take the field in a new direction, Dr. Kraus said.

"Our research shows that PARP-1 also plays a role in normal physiological processes and normal cellular functions. It's an important component of the cellular machinery that senses and responds to the environment," he said.

While studies in mouse models show PARP-1 is not essential for life, it becomes important when an organism needs to adapt to changing environmental or physiological cues, such as developmental processes or altered diet, Dr. Kraus said.

Understanding how PARP-1 works could one day help researchers find ways to target the protein to treat metabolic disorders or obesity, he said.

The two new UT Southwestern studies outline for the first time the exact molecular mechanisms of PARP-1's roles in inhibiting the formation of fat cell precursors and in maintaining stem cells. Here are the key findings:

  • The first study identifies amino acids on C/EBPb (a key transcription factor required for formation) that are chemically modified by PARP-1's enzymatic activity through a process called ADP-ribosylation. Modification of C/EBPb interferes with the differentiation of precursor cells into fat , according to the study.
  • The second study reports how PARP-1 regulates embryonic stem cell self-renewal and pluripotency (ability to become different cell types), but without using its enzymatic activity. Instead, in this case, PARP-1 functions as a structural component of chromosomes in the nucleus, creating binding sites for the critical embryonic stem cell transcription factor Sox2. This action allows transcription of genes necessary to maintain the ability of to continue self-renewing, rather than becoming a specific cell type, the research shows.

Explore further: Expanded role of PARP proteins opens the door to explore therapeutic targets in cancer

Related Stories

Expanded role of PARP proteins opens the door to explore therapeutic targets in cancer

August 15, 2016
Using technology they developed, UT Southwestern Medical Center researchers have identified a previously unknown role of a certain class of proteins: as regulators of gene activity and RNA processing.

Murine study finds potential boost for ovarian cancer drug Olaparib

January 25, 2017
Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer ...

New findings may enhance PARP inhibitors therapy in breast cancer

January 18, 2016
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed ...

Sleep proteins in new DNA repair mechanism

October 2, 2015
Researchers at Karolinska Institutet and universities in Hong Kong have found a new molecular mechanism for DNA repair involving an unexpected interaction between the PARP-1 protein and sleep proteins in humans. Their discovery ...

A gene defect as a potential gateway for targeted prostate cancer therapy

September 5, 2016
The loss of CHD1, one of the most frequently mutated genes in prostate tumors, sensitizes human prostate cancer cells to different drugs, including PARP inhibitors. This suggests CHD1 as a potential biomarker for targeted ...

Recommended for you

Scientists create better laboratory tools to study cancer's spread

April 23, 2018
Cancer that has spread, or metastasized, from its original site to other tissues and organs in the body is a leading cause of cancer death. Unfortunately, research focused on metastatic disease has been limited by a lack ...

The role of 'extra' DNA in cancer evolution and therapy resistance

April 23, 2018
Glioblastoma (GBM) is the most common and aggressive form of brain cancer. Response to standard-of-care treatment is poor, with a two-year survival rate of only 15 percent. Research is beginning to provide a better understanding ...

Size, structure help poziotinib pose threat to deadly exon 20 lung cancer

April 23, 2018
A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable form of the disease, researchers at The University of Texas MD Anderson Cancer ...

How to hijack degrading complexes to put cancer cells asleep

April 23, 2018
Newcastle and Dundee University researchers have uncovered an alternative path of how the breast cancer drug palbociclib drives malignant cells into cell death, senescence.

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.